Sp1-mediated microRNA-182 expression regulates lung cancer progression

Oncotarget

Volumn 5, Issue 3, 2014, Pages 740-753

  Yang, Wen Bin ^a   Chen, Ping Hsin ^b   Hsu, Tsung I ^a   Fu, Tzu Fun ^b   Su, Wu Chou ^b   Liaw, Hungjiun ^a   Chang, Wen Chang ^c   Hung, Jan Jong ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

FOXO3; Lung cancer; MiR 182; Sp1

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA; MICRORNA 182; NERVE CELL ADHESION MOLECULE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR SP1; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MICRORNA; MIRN182 MICRORNA, HUMAN; SP1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADAM9 GENE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CD44 GENE; CDH9 GENE; CELL MIGRATION; CONTROLLED STUDY; FOXO3 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; METASTASIS; METASTASIS INHIBITION; PROTEIN EXPRESSION; SP1 GENE; TUMOR INVASION; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CULTURE TECHNIQUE; DISEASE COURSE; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL CULTURE TECHNIQUES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MICRORNAS; SP1 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84896844569     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1608     Document Type: Article

References (58)

1. Halbeisen RE, Galgano A, Scherrer T and Gerber AP. Posttranscriptional gene regulation: from genome-wide studies to principles. Cell Mol Life Sci. 2008; 65(5):798-813.
2. Loya CM, Van Vactor D and Fulga TA. Understanding neuronal connectivity through the post-transcriptional toolkit. Genes Dev. 2010; 24(7):625-635.
3. Jewer M, Findlay SD and Postovit LM. Post-transcriptional regulation in cancer progression: Microenvironmental control of alternative splicing and translation. J Cell Commun Signal. 2012; 6(4):233-248.
4. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002; 30(4):363-364.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-233.
6. Suzuki H, Maruyama R, Yamamoto E and Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012; 6(6):567-578.
7. Chen PS, Su JL and Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci. 2012; 19:90.
8. Kopp F, Wagner E and Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget. 2013.
9. Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A and Annilo T. Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2013; 132(12):2884-2893.
10. Abd-El-Fattah AA, Sadik NA, Shaker OG and Aboulftouh ML. Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia. Cell Biochem Biophys. 2013.
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
12. Rosell R, Bivona TG and Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013; 382(9893):720-731.
13. McFarlane C, McFarlane S, Paul I, Arthur K, Scheaff M, Kerr K, Stevenson M, Fennell DA and Johnston JA. The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget. 2013; 4(10):1836-1843.
14. Shen J, Stass SA and Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013; 329(2):125-136.
15. Boeri M, Pastorino U and Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012; 18(3):268-274.
16. Melo SA and Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res. 2012; 18(16):4234-4239.
17. Giordano S and Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013; 57(2):840-847.
18. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH and Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051-4060.
19. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-626.
20. Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC and Kung HF. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett. 2013; 331(1):1-10.
21. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT and Giaccia AJ. Hypoxiainducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009; 35(6):856-867.
22. Chang WC and Hung JJ. Functional role of posttranslational modifications of Sp1 in tumorigenesis. J Biomed Sci. 2012; 19:94.
23. Hsu TI, Wang MC, Chen SY, Huang ST, Yeh YM, Su WC, Chang WC and Hung JJ. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol Pharmacol. 2012; 82(6):1115-1128.
24. Yan GZ and Ziff EB. Nerve growth factor induces transcription of the p21 WAF1/CIP1 and cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor. J Neurosci. 1997; 17(16):6122-6132.
25. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y and Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene. 2005; 24(56):8277-8290.
26. Nicolas M, Noe V, Jensen KB and Ciudad CJ. Cloning and characterization of the 5'-flanking region of the human transcription factor Sp1 gene. J Biol Chem. 2001; 276(25):22126-22132.
27. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010; 17(4):333-347.
28. Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, Zhou WP, Wang F and Sun SH. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology. 2011; 54(6):2025-2035.
29. Xu X, Wang S, Liu J, Dou D, Liu L, Chen Z, Ye L, Liu H, He Q, Raj JU and Gao Y. Hypoxia induces downregulation of soluble guanylyl cyclase beta1 by miR-34c-5p. J Cell Sci. 2012; 125(Pt 24):6117-6126.
30. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J and Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011; 32(8):1183-1189.
31. Xu Z, Xiao SB, Xu P, Xie Q, Cao L, Wang D, Luo R, Zhong Y, Chen HC and Fang LR. miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kappaB. J Biol Chem. 2011; 286(24):21401-21412.
32. Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC and Hung JJ. Sp1 expression regulates lung tumor progression. Oncogene. 2012; 31(35):3973-3988.
33. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC and Hung JJ. Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol. 2008; 380(5):869-885.
34. Maraver A and Serrano M. Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC). Oncotarget. 2012; 3(9):917-918.
35. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A. 2009; 106(6):1814-1819.
36. Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM, Esau C, Vanderburg C and Krichevsky AM. De-repression of FOXO3a death axis by microRNA-132 and-212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet. 2013.
37. Zhang L, Liu T, Huang Y and Liu J. microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int J Mol Med. 2011; 28(3):381-388.
38. Sun Y, Fang R, Li C, Li L, Li F, Ye X and Chen H. Hsamir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun. 2010; 396(2):501-507.
39. Thomas M, Lieberman J and Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol. 2010; 17(10):1169-1174.
40. Chuang JY, Wu CH, Lai MD, Chang WC and Hung JJ. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer. 2009; 125(9):2066-2076.
41. Wang J, Li J, Shen J, Wang C, Yang L and Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012; 12:227.
42. Zeisberg M and Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest. 2009; 119(6):1429-1437.
43. Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L and Stetler-Stevenson WG. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget. 2013; 4(1):163-173.
44. Williams K, Motiani K, Giridhar PV and Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013; 238(3):324-338.
45. Liu J, Xiao Z, Wong SK, Tin VP, Ho KY, Wang J, Sham MH and Wong MP. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget. 2013; 4(10):1698-1711.
46. Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C and Chung LW. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 2011; 71(3):232-240.
47. Pacheco-Pinedo EC and Morrisey EE. Wnt and Kras signaling-dark siblings in lung cancer. Oncotarget. 2011; 2(7):569-574.
48. Thedieck C, Kalbacher H, Kuczyk M, Muller GA, Muller CA and Klein G. Cadherin-9 is a novel cell surface marker for the heterogeneous pool of renal fibroblasts. PLoS One. 2007; 2(7):e657.
49. Guttilla IK and White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009; 284(35):23204-23216.
50. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57.
51. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37(1):1-13.
52. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H and Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009; 69(14):5776-5783.
53. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM and Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-198.
54. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011; 17(21):6802-6811.
55. Cho WC, Chow AS and Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009; 45(12):2197-2206.
56. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P and Jen J. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012; 18(13):3658-3667.
57. Ma L, Huang Y, Zhu W, Zhou S, Zhou J, Zeng F, Liu X, Zhang Y and Yu J. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 2011; 6(10):e26502.
58. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma A, Kudoh S, Croce CM and Harris CC. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009; 106(29):12085-12090.